MS 1601A
Alternative Names: MS-1061ALatest Information Update: 28 Sep 2023
At a glance
- Originator MedPacto
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in South Korea
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in South Korea
- 09 Jan 2020 MS 1601A is available for licensing as of 09 Jan 2020. http://www.medpacto.com/page/s3/s1.php- MedPacto pipeline, January 2020